Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ARCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ARCT

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Arcturus Therapeutics Holdings Inc

ARCT
Current price
13.54 USD +0.67 USD (+5.21%)
Last closed 13.15 USD
ISIN US03969T1097
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 348 499 712 USD
Yield for 12 month -42.19 %
1Y
3Y
5Y
10Y
15Y
ARCT
21.11.2021 - 28.11.2021

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Address: 10628 Science Center Drive, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

67.40 USD

P/E Ratio

Dividend Yield

Financials ARCT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ARCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+138 389 000 USD

Last Year

+157 748 000 USD

Current Quarter

+29 382 000 USD

Last Quarter

+21 000 000 USD

Current Year

+134 845 000 USD

Last Year

+154 791 000 USD

Current Quarter

+29 382 000 USD

Last Quarter

+20 181 000 USD
EBITDA -78 642 000 USD
Operating Margin TTM -57.27 %
Price to Earnings
Return On Assets TTM -13.67 %
PEG Ratio
Return On Equity TTM -27.40 %
Wall Street Target Price 67.40 USD
Revenue TTM 143 680 000 USD
Book Value 8.62 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -22.70 %
Dividend Yield
Gross Profit TTM -32 796 000 USD
Earnings per share -2.52 USD
Diluted Eps TTM -2.52 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -47.47 %

Stock Valuation ARCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 2.48
Enterprise Value Revenue 1.42
Price Sales TTM 2.43
Enterprise Value EBITDA -25.67
Price Book MRQ 1.54

Technical Indicators ARCT

For 52 Weeks

8.04 USD 25.88 USD
50 Day MA 12.62 USD
Shares Short Prior Month 4 965 290
200 Day MA 15.58 USD
Short Ratio 10.37
Shares Short 5 039 101
Short Percent 28.32 %